Zydus Lifesciences Receives USFDA Approval for Generic Ivermectin and Dapsone Tablets

Zydus Lifesciences has received final approval from the US Food and Drug Administration to market generic Ivermectin Tablets USP, 3 mg, and Dapsone Tablets USP, 25 mg and 100 mg. Ivermectin is used to treat parasitic worm infections such as intestinal strongyloidiasis and onchocerciasis, while Dapsone treats leprosy and dermatitis herpetiformis. Both drugs will be manufactured at Zydus's Ahmedabad facilities and distributed by Viona Pharmaceuticals Inc. The approved drugs have notable annual sales in the US market.